Skip to main content

Table 2 B. breve skews the immune response away from Th2 and towards Treg in lungs of chronically asthmatic mice

From: Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma

Treatment Ratio OVA/Sal OVA/OVA
   Mean ratio SEM Mean ratio SEM
PBS Gata3/Tbet 1.03 0.10 1.66# 0.37
  Foxp3/Rorγt 0.82 0.09 0.29 0.20
  Foxp3/Gata3 0.83 0.09 0.41 0.28
  Foxp3/Tbet 0.86 0.09 0.69 0.47
B. breve Gata3/Tbet 0.83 0.14 0.29¤, ‡ 0.02
  Foxp3/Rorγt 1.62 0.36 2.36¤ 1.04
  Foxp3/Gata3 1.65 0.36 2.92¤ 1.29
  Foxp3/Tbet 1.36 0.30 0.83 0.37
budesonide Gata3/Tbet 0.78 0.10 1.34 0.11
  Foxp3/Rorγt 0.59 0.02 1.26 0.04
  Foxp3/Gata3 0.66 0.02 1.00 0.03
  Foxp3/Tbet 0.51 0.02 1.35 0.04
L. rhamnosus Gata3/Tbet 0.86 0.06 0.83¤ 0.08
  Foxp3/Rorγt 1.02 0.22 1.07 0.21
  Foxp3/Gata3 0.98 0.21 1.11 0.20
  Foxp3/Tbet 0.84 0.18 0.92 0.18
  1. Ratios for Gata3/Tbet (Th2/Th1), Foxp3/Rorγt (Treg/Th17), Foxp3/Gata3 (Treg/Th2) and Foxp3/Tbet (Treg/Th1) mRNA expression in whole lung tissue are shown for OVA/Sal and OVA/OVA mice for each treatment. Data is represented as mean ratio ± SEM, n = 6 mice/group. The mean ratio was calculated by dividing the individual expression values for the first transcription factor (numerator) by the mean expression value for the second transcription factor (denominator). Statistical significance of differences was tested using post hoc Bonferroni’s multiple comparison test after one-way ANOVA. #Statistically significant difference (p < 0.05) compared to the OVA/Sal-PBS group. ¤Statistically significant difference (p < 0.05) compared to the OVA/OVA-PBS group. Statistically significant difference (p < 0.05) compared to OVA/Sal mice in each treatment group.